High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1451-1457

  Kara, Hasan ^a   Akinci, Murat ^a   Degirmenci, Selim ^a   Bayir, Aysegul ^a   Ak, Ahmet ^a   Nayman, Alaaddin ^a   Unlu, Ali ^a   Akyurek, Fikret ^a   Sivri, Mesut ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Biomarker; Cerebrovascular accident; Inflammation

Indexed keywords

C REACTIVE PROTEIN; PHOSPHOLIPASE A2;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CALIBRATION; CONSCIOUSNESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; ELECTROCARDIOGRAM; EMERGENCY HEALTH SERVICE; ENZYME ACTIVITY; FEMALE; GLASGOW COMA SCALE; HUMAN; HYPERTENSION; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE;

EID: 84905639244     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S67665     Document Type: Article

References (34)

1. Yoldas T, Gonen M, Godekmerdan A, Ilhan F, Bayram E. The serum high-sensitive C reactive protein and homocysteine levels to evaluate the prognosis of acute ischemic stroke. Mediators Inflamm. 2007; 2007: 15929.
2. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC; BRAIN Study Group. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke. 2009; 40(1): 77-85.
3. Korkmaz I, Eren ŞH, Güven FM, Seǧmen H. The clinical significance of multimarker index for early diagnosis among the patients admitted to the emergency department with suspected stroke. Balkan Med J. 2011; 28(1): 33-36.
4. Fiebach JB, Schellinger PD, Jansen O, et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke. 2002; 33(9): 2206-2210.
5. Kruetzelmann A, Köhrmann M, Sobesky J, et al. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke. Stroke. 2011; 42(5): 1251-1254.
6. Katzan IL, Hammer MD, Hixson ED, et al; Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004; 61(3): 346-350.
7. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2): 115-126.
8. Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am J Cardiol. 2008; 101(12A): 11F-22F.
9. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006; 166(19): 2073-2080.
10. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005; 165(21): 2479-2484.
11. Jensen MB, Chacon MR, Sattin JA, Levine RL, Vemuganti R. Potential biomarkers for the diagnosis of stroke. Expert Rev Cardiovasc Ther. 2009; 7(4): 389-393.
12. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3): 89-95.
13. Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol. 2008; 101(12A): 34F-40F.
14. Wildgruber M, Swirski FK, Zernecke A. Molecular imaging of inflammation in atherosclerosis. Theranostics. 2013; 3(11): 865-884.
15. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001; 32(11): 2575-2579.
16. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004; 35(1): 57-63.
17. Zaremba J, Losy J. Interleukin-18in acute ischaemic stroke patients. Neurol Sci. 2003; 24(3): 117-124.
18. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol. 2005; 62(7): 1130-1134.
19. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J Neuroendocrinol. 2013; 25(9): 771-778.
20. Zi WJ, Shuai J. Plasma D-dimer levels are associated with stroke subtypes and infarction volume in patients with acute ischemic stroke. PLoS One. 2014; 9(1): e86465.
21. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke. 2006; 37(4): 1113-1115.
22. Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008; 39(8): 2280-2287.
23. Yamagami H, Kitagawa K, Hoshi T, et al. Associations of serum IL-18levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol. 2005; 25(7): 1458-1462.
24. Gürkaş E, Orhan G, Ak F. [Association between interleukin-18 levels and early and late clinical findings and infarction volume in patients with acute ischemic stroke]. Türk Beyin Damar Hastali{dotless}klari{dotless} Dergisi. 2012; 18(1): 10-15. Turkish.
25. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000; 31(10): 2325-2329.
26. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336(14): 973-979.
27. Khan A, Ali Z. Frequency of raised C-reactive protein in acute ischemic stroke. Khyber Med Univ J. 2012; 4(2): 45-48.
28. Youn CS, Choi SP, Kim SH, et al. Serum highly selective C-reactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. Am J Emerg Med. 2012; 30(1): 124-128.
29. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005; 111(5): 570-575.
30. Furie KL, Parides MK, Greer DM, et al. Lipoprotein-associated phospholipase A2 activity predicts early stroke recurrence [2007 International Stroke Conference abstract 20]. Stroke. 2007; 38(2): 458.
31. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke. 2002; 33(10): 2459-2464.
32. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 1999; 30(6): 1190-1195.
33. Sahan M, Sebe A, Acikalin A, et al. Acute-phase reactants and cytokines in ischemic stroke: do they have any relationship with short-term mortality? Eur Rev Med Pharmacol Sci. 2013; 17(20): 2773-2777.
34. Saposnik G, Kapral MK, Liu Y, et al; Investigators of the Registry of the Canadian Stroke Network; Stroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation. 2011; 123(7): 739-749.